Lupin

₹1,997As of Sun 8 Nov 2026, 12:00 UTC
NSE:LUPINHealthcare
Country India
PE (Fwd) 14.11
TSR 10Y CAGR 3.39%
Div yield 0.90%
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.16
PE TTM 17.15
TSR TTM 2.44%
Mkt cap ₹925.0B
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
₹2,177
9.04%
(56.10%)
Price above Reference Value
FY23
FY24
FY25
FY26
Earnings per share₹
9.41
41.87
71.69
116.44
127.96%
344.95%
71.22%
62.42%
Revenue₹B
166.4
200.1
227.1
279.6
1.44%
20.25%
13.48%
23.12%
TTM
FYE 31 Mar INR
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
FY2027E
Trend
5Y
10Y
Peers
279.6
Revenue₹B
—
—
—
—
—
164.1
166.4
200.1
227.1
279.6
304.8
14.26%
14.26%
57
23.12
Revenue growth%
—
—
—
—
—
—
1.44
20.25
13.48
23.12
9.03
16.86
—
83
71.51
Gross margin%
—
—
—
—
—
57.94
56.54
64.46
67.50
71.51
71.47
64.46
64.46
77
24.57
Operating margin%
—
—
—
—
—
7.67
5.12
13.87
18.35
24.57
24.49
13.87
13.87
73
19.07
Net margin%
—
—
—
—
—
(9.31)
2.58
9.57
14.45
19.07
19.45
9.57
9.57
70
17.15
P/E ratio (avg)x
—
—
—
—
—
—
72.79
28.53
27.59
17.61
15.43
28.06
—
80
13.31
EV/EBITx
—
—
—
—
—
35.99
36.73
19.68
21.73
13.67
12.25
21.73
21.73
86
—
FCF yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
77
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
67
—
FCF / Net incomex
—
—
—
—
—
—
—
—
—
—
—
—
—
64
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
90
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
90
—
Return on assets%
—
—
—
—
—
—
—
—
—
—
—
—
—
90
116.44
EPS₹
—
—
—
—
—
(33.65)
9.41
41.87
71.69
116.44
129.43
131.28%
131.28%
—
62.43
EPS growth%
—
—
—
—
—
—
127.97
344.87
71.21
62.43
11.16
99.59
—
60
—
Bookvalue per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
18.00
Dividend per sh₹
—
—
—
—
—
4.00
4.00
8.00
12.00
18.00
19.74
45.65%
45.65%
—
0.90
Div yield (avg)%
—
—
—
—
—
0.40
0.58
0.67
0.61
0.88
0.99
0.61
0.61
41
15.46
Payout ratio%
—
—
—
—
—
—
42.51
19.11
16.74
15.46
15.25
17.92
—
25
458.0
Shares (diluted)M
—
—
—
—
—
454.0
456.9
457.2
457.8
458.0
◌458.0
0.22%
0.22%
31
(0.05)
Buyback yield%
—
—
—
—
—
—
(0.64)
(0.06)
(0.12)
(0.05)
◌—
(0.09)
—
31
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
47
914.6
Enterprise value₹B
—
—
—
—
—
452.8
313.0
546.3
905.4
939.2
914.6
20.01%
20.01%
47
—
LT debt₹M
—
—
—
—
—
—
—
—
—
—
—
—
—
50
Peers (US$9.689B)
Cap (US$)
PE
11.17B
46.83x
11.03B
26.08x
8.695B
32.35x
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
18.19
15.04
15.04
Own earn%
—
—
—
Sh yield%
0.85
0.55
0.55
Owners
Insiders/Inst%
1.39
39.24
Short interest%
—
SBC / revenue%
0.32
Record
10Y
Profitable years
4/5
Revenue growth years
4/4
EPS growth years
4/4
Dividend streakyrs
2
Op margin range%
5–25
$1 testx
—
Incr. ROIC%
—

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).

Growth vs revenue
Latest
Trend
4Y CAGR
Rel growth
Revenue
₹279.6B
14.26%
1.00×
Cost of revenue
₹79.65B
3.65%
0.68×
Operating expenses
₹131.2B
12.31%
0.93×
Revenue by region
No breakdown available
Reinvestment returns
n/m
Trend
Reinvestment rate
n/m
-
Return on capital
n/m
-
Spread over hurdle
n/m
-